At a glance
ClinicalIndex Comparison RecordPhase 1Recruiting· 20 target
Drug / intervention
AlloRxbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
NCT05147779Phase 1RecruitingUpdate OverdueUpdated 14mo ago · Completion was 6mo agoEnrollment Stalled
Long Recruiting
Update Overdue
Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for the Treatment of Peyronie's Disease, Erectile Dysfunction, and Interstitial Cystitis
The Foundation for Orthopaedics and Regenerative Medicine·interventional·Posted Dec 7, 2021·Updated Apr 17, 2025
In Brief
A Phase 1 clinical trial evaluating AlloRx for Erectile Dysfunction and 2 related conditions. Currently recruiting, targeting 20 participants across 1 site.
Signals
Enrollment appears stalled
Detailed Summary
This trial will study the safety and efficacy of intravenous and intracavernosal or interstitial delivery of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Peyronie's disease, erectile dysfunction , and Interstitial Cystitis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAntigua and Barbuda
Collaborators--
Timeline
Phase 1RecruitingOverdue
20222023202420252026
Enrollment StartSep 2021
First PostedDec 2021
Primary CompletionDec 2025
TodayJul 2026
First PostedDec 7, 2021
Enrollment StartSep 12, 2021
Primary CompletionDec 1, 2025
TodayJul 1, 2026
Enrollment to primary: 4.2 yearsPosted 4.6 years ago
Interventions
AlloRxbiological
cultured allogeneic adult umbilical cord derived mesenchymal stem cells